Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts

Drug Dev Ind Pharm. 1999 Feb;25(2):163-8. doi: 10.1081/ddc-100102156.

Abstract

The effects of powder substrate composition on the in vitro release properties of methyclothiazide liquisolid compacts were evaluated. The dissolution patterns of this water-insoluble drug formulated in liquisolid tablets were also compared to those of commercial products. According to the new liquisolid technique, liquid medications such as solutions or suspensions of water-insoluble drugs in suitable nonvolatile liquid vehicles can be converted into acceptably flowing and readily compressible powders by a simple admixture with certain powder substrates, which are selected powders referred to as the carrier and coating materials. Enhanced release profiles may be exhibited by such systems due to the increased wetting properties and surface of drug available for dissolution. Liquisolid tablets of methyclothiazide containing a 5% w/w drug solution in polyethylene glycol 400 were prepared using powder substrates of different excipient ratios. The release rates of such products were assessed using the USP dissolution test and were compared to those of their commercial counterparts. It was observed that maximum drug dissolution rates can be exhibited by systems that have powder substrates with optimum carrier-to-coating ratios. In addition, liquisolid tablets displayed significantly enhanced dissolution profiles compared to those of marketed products.

Publication types

  • Comparative Study

MeSH terms

  • Chemistry, Pharmaceutical
  • Diuretics
  • Dosage Forms
  • Drug Delivery Systems*
  • Excipients
  • Methyclothiazide / administration & dosage*
  • Methyclothiazide / pharmacokinetics
  • Powders / pharmacology*
  • Sodium Chloride Symporter Inhibitors / administration & dosage*
  • Sodium Chloride Symporter Inhibitors / pharmacokinetics
  • Solubility
  • Tablets

Substances

  • Diuretics
  • Dosage Forms
  • Excipients
  • Powders
  • Sodium Chloride Symporter Inhibitors
  • Tablets
  • Methyclothiazide